TY - JOUR
TI - Effects of Interleukin 17A Inhibition on Myocardial Deformation and Vascular Function in Psoriasis
AU - Makavos, G.
AU - Ikonomidis, I.
AU - Andreadou, I.
AU - Varoudi, M.
AU - Kapniari, I.
AU - Loukeri, E.
AU - Theodoropoulos, K.
AU - Pavlidis, G.
AU - Triantafyllidi, H.
AU - Thymis, J.
AU - Parissis, J.
AU - Tsoumani, M.
AU - Rafouli-Stergiou, P.
AU - Katsimbri, P.
AU - Papadavid, E.
JO - Canadian Journal of Cardiology
PY - 2020
VL - 36
TODO - 1
SP - 100-111
PB - HANLEY & BELFUS-ELSEVIER INC
SN - 0828-282X
TODO - 10.1016/j.cjca.2019.06.021
TODO - carbonyl derivative;  cyclosporine;  interleukin 17;  malonaldehyde;  methotrexate;  secukinumab;  biological marker;  IL17A protein, human;  immunosuppressive agent;  interleukin 17;  monoclonal antibody;  secukinumab, adult;  arterial stiffness;  Article;  comparative study;  controlled study;  coronary flow reserve;  diastole;  female;  heart left ventricle function;  heart performance;  human;  major clinical study;  male;  myocardial disease;  oxidative stress;  Psoriasis Area and Severity Index;  psoriasis vulgaris;  psoriatic arthritis;  pulse wave;  blood;  brachial artery;  diagnostic imaging;  echocardiography;  heart left ventricle function;  heart ventricle;  middle aged;  pathophysiology;  physiology;  procedures;  prognosis;  psoriasis;  randomized controlled trial, Antibodies, Monoclonal, Humanized;  Biomarkers;  Brachial Artery;  Cyclosporine;  Echocardiography;  Female;  Heart Ventricles;  Humans;  Immunosuppressive Agents;  Interleukin-17;  Male;  Methotrexate;  Middle Aged;  Prognosis;  Psoriasis;  Pulse Wave Analysis;  Vascular Stiffness;  Ventricular Function, Left
TODO - Background: Interleukin (IL)-17A activity is implicated in psoriasis. We investigated the effects of IL-17A inhibition on vascular and left ventricular (LV) function in patients with psoriasis. Methods: A total of 150 patients with psoriasis received either an anti-IL-17A agent (secukinumab, n = 50), cyclosporine (n = 50), or methotrexate treatment (n = 50). At baseline and after 4 and 12 months of treatment, we measured (1) LV global longitudinal strain (GLS), GLS rate (GLSR), GLSR at early diastole, LV twisting, and untwisting; (2) coronary flow reserve (CFR); (3) pulse wave velocity (PWV); and (4) malondialdehyde and protein carbonyl as markers of oxidative stress. Results: Compared with cyclosporine and methotrexate, anti-IL-17A treatment resulted in a greater increase in GLS at 4 and 12 months after treatment (10% and 14% with anti-IL-17A vs 2% and 2% with cyclosporine vs 4% and 4% with methotrexate, respectively), GLSR, GLSR at early diastole (45% and 41% vs 5% and 4% vs 7% and 9%, respectively), and LV twisting (32% and 28% vs 6% and 8% vs 7% and 6%, respectively) (P < 0.05). Anti-IL-17A treatment resulted in greater improvement of CFR and PWV than cyclosporine or methotrexate (P < 0.05). PWV increased after cyclosporine treatment (+11% at 4 and +14% and 12 months) (P < 0.05). Markers of oxidative stress were reduced only after anti-IL-17A treatment (P < 0.05). Changes of myocardial deformation markers and CFR after anti-IL-17A treatment correlated with a concomitant reduction of oxidative stress. Conclusions: In psoriasis, inhibition of IL-17A results in a greater improvement of vascular and myocardial function compared with cyclosporine or methotrexate treatment, indicating a beneficial effect on overall cardiovascular function. © 2019 Canadian Cardiovascular Society
ER -